ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025

ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025

Proposed dividend of €0.11 per share, up +120%, reflecting the Company’s improved financial performance and solid financial position

Regulatory News:

ABL Diagnostics (Euronext Paris – FR001400AHX6), a company specialized in molecular diagnostics for infectious diseases, announces that its Board of Directors, at its meeting held on April 30, 2026, has decided to propose to the Combined General Meeting to be held on June 30, 2026 the distribution of a dividend of €0.11 per share for the financial year ended December 31, 2025.

This proposal, which remains subject to shareholders’ approval, is in line with the Company’s dividend policy, following the first dividend paid in respect of FY2024 in the amount of €0.05 per share. It reflects ABL Diagnostics’ intention to establish a sustainable shareholder return, consistent with its development and financial position.